

# Larry J Anderson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2707302/publications.pdf>

Version: 2024-02-01

86  
papers

12,386  
citations

61984

43  
h-index

58581

82  
g-index

89  
all docs

89  
docs citations

89  
times ranked

11883  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 179.	7.4	3,197
2	Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. <i>Science</i> , 2003, 300, 1394-1399.	12.6	2,238
3	Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. <i>Nature Immunology</i> , 2000, 1, 398-401.	14.5	1,482
4	Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993-2008. <i>Clinical Infectious Diseases</i> , 2012, 54, 1427-1436.	5.8	475
5	Involvement of Toll-Like Receptor 4 in Innate Immunity to Respiratory Syncytial Virus. <i>Journal of Virology</i> , 2001, 75, 10730-10737.	3.4	447
6	CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. <i>Nature Immunology</i> , 2001, 2, 732-738.	14.5	380
7	Respiratory Syncytial Virus-associated Hospitalizations Among Infants and Young Children in the United States, 1997-2006. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 5-9.	2.0	286
8	Real-Time Reverse Transcription-Polymerase Chain Reaction Assay for SARS-associated Coronavirus. <i>Emerging Infectious Diseases</i> , 2004, 10, 311-316.	4.3	279
9	Application of TaqMan Low-Density Arrays for Simultaneous Detection of Multiple Respiratory Pathogens. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2175-2182.	3.9	201
10	Substantial variability in community respiratory syncytial virus season timing. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, 857-863.	2.0	160
11	Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach. <i>Cell Reports</i> , 2018, 22, 2504-2517.	6.4	150
12	Respiratory Syncytial Virus G and/or SH Protein Alters Th1 Cytokines, Natural Killer Cells, and Neutrophils Responding to Pulmonary Infection in BALB/c Mice. <i>Journal of Virology</i> , 1999, 73, 7099-7107.	3.4	145
13	Respiratory Syncytial Virus G Protein and G Protein CX3C Motif Adversely Affect CX3CR1+ T Cell Responses. <i>Journal of Immunology</i> , 2006, 176, 1600-1608.	0.8	127
14	Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice. <i>Journal of Infectious Diseases</i> , 2009, 200, 439-447.	4.0	115
15	CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. <i>Journal of General Virology</i> , 2015, 96, 2543-2556.	2.9	110
16	Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P. <i>Journal of Virology</i> , 2003, 77, 9831-9844.	3.4	109
17	Protective Activity of a Human Respiratory Syncytial Virus Immune Globulin Prepared from Donors Screened by Microneutralization Assay. <i>Journal of Infectious Diseases</i> , 1992, 165, 456-463.	4.0	106
18	Respiratory Syncytial Virus G and/or SH Glycoproteins Modify CC and CXC Chemokine mRNA Expression in the BALB/c Mouse. <i>Journal of Virology</i> , 2000, 74, 6227-6229.	3.4	89

#	ARTICLE	IF	CITATIONS
19	Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients. <i>Journal of Immunology</i> , 2009, 183, 6338-6345.	0.8	87
20	Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice. <i>Journal of Virology</i> , 2010, 84, 1148-1157.	3.4	87
21	Differences in the Nasopharyngeal Microbiome During Acute Respiratory Tract Infection With Human Rhinovirus and Respiratory Syncytial Virus in Infancy. <i>Journal of Infectious Diseases</i> , 2016, 214, 1924-1928.	4.0	84
22	Respiratory Syncytial Virus G Protein CX3C Motif Impairs Human Airway Epithelial and Immune Cell Responses. <i>Journal of Virology</i> , 2013, 87, 13466-13479.	3.4	82
23	The G Glycoprotein of Respiratory Syncytial Virus Depresses Respiratory Rates through the CX3C Motif and Substance P. <i>Journal of Virology</i> , 2003, 77, 6580-6584.	3.4	81
24	Respiratory Syncytial Virus Infection and G and/or SH Protein Expression Contribute to Substance P, Which Mediates Inflammation and Enhanced Pulmonary Disease in BALB/c Mice. <i>Journal of Virology</i> , 2000, 74, 1614-1622.	3.4	77
25	Peripheral Blood Mononuclear Cells from Infants Hospitalized Because of Respiratory Syncytial Virus Infection Express T Helper <sup>1</sup> and T Helper <sup>2</sup> Cytokines and CC Chemokine Messenger RNA. <i>Journal of Infectious Diseases</i> , 2002, 185, 1388-1394.	4.0	77
26	Respiratory Syncytial Virus whole-genome sequencing identifies convergent evolution of sequence duplication in the C-terminus of the G gene. <i>Scientific Reports</i> , 2016, 6, 26311.	3.3	77
27	Nasopharyngeal Lactobacillus is associated with a reduced risk of childhood wheezing illnesses following acute respiratory syncytial virus infection in infancy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1447-1456.e9.	2.9	74
28	The Morphology and Assembly of Respiratory Syncytial Virus Revealed by Cryo-Electron Tomography. <i>Viruses</i> , 2018, 10, 446.	3.3	69
29	Interference Between Respiratory Syncytial Virus and Human Rhinovirus Infection in Infancy. <i>Journal of Infectious Diseases</i> , 2017, 215, 1102-1106.	4.0	68
30	Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab <sup>2</sup> ) <sub>2</sub> components mediates reduced pulmonary inflammation in mice. <i>Journal of General Virology</i> , 2009, 90, 1119-1123.	2.9	64
31	Prophylactic Treatment with a G Glycoprotein Monoclonal Antibody Reduces Pulmonary Inflammation in Respiratory Syncytial Virus (RSV)-Challenged Naïve and Formalin-Inactivated RSV-Immunized BALB/c Mice. <i>Journal of Virology</i> , 2010, 84, 9632-9636.	3.4	64
32	Nasopharyngeal Microbiome in Respiratory Syncytial Virus Resembles Profile Associated with Increased Childhood Asthma Risk. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1180-1183.	5.6	63
33	An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. <i>Virology</i> , 2015, 483, 117-125.	2.4	60
34	Infant Viral Respiratory Infection Nasal Immune-Response Patterns and Their Association with Subsequent Childhood Recurrent Wheeze. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1064-1073.	5.6	56
35	Minimally Invasive Sampling Method Identifies Differences in Taxonomic Richness of Nasal Microbiomes in Young Infants Associated with Mode of Delivery. <i>Microbial Ecology</i> , 2016, 71, 233-242.	2.8	54
36	A Respiratory Syncytial Virus (RSV) Anti-G Protein F(ab <sup>2</sup> ) <sub>2</sub> Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-Infected BALB/c Mice. <i>Journal of Virology</i> , 2013, 87, 10955-10967.	3.4	53

#	ARTICLE	IF	CITATIONS
37	Respiratory syncytial virus vaccine development. <i>Seminars in Immunology</i> , 2013, 25, 160-171.	5.6	50
38	Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop. <i>Vaccine</i> , 2016, 34, 4843-4849.	3.8	49
39	Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2013, 372, 391-404.	1.1	48
40	Prophylaxis with a Respiratory Syncytial Virus (RSV) Anti-G Protein Monoclonal Antibody Shifts the Adaptive Immune Response to RSV rA2-line19F Infection from Th2 to Th1 in BALB/c Mice. <i>Journal of Virology</i> , 2014, 88, 10569-10583.	3.4	48
41	Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease. <i>PLoS ONE</i> , 2013, 8, e74905.	2.5	46
42	Human Rhinovirus Induced Cytokine/Chemokine Responses in Human Airway Epithelial and Immune Cells. <i>PLoS ONE</i> , 2014, 9, e114322.	2.5	46
43	Objectives, design and enrollment results from the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE). <i>BMC Pulmonary Medicine</i> , 2015, 15, 45.	2.0	45
44	Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFN $\gamma$ priming. <i>Blood Advances</i> , 2017, 1, 628-643.	5.2	43
45	Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development. <i>Frontiers in Immunology</i> , 2019, 10, 1675.	4.8	39
46	Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice. <i>PLoS ONE</i> , 2012, 7, e51485.	2.5	37
47	Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model. <i>Antiviral Research</i> , 2018, 154, 149-157.	4.1	36
48	Response to Rhinovirus Infection by Human Airway Epithelial Cells and Peripheral Blood Mononuclear Cells in an In Vitro Two-Chamber Tissue Culture System. <i>PLoS ONE</i> , 2013, 8, e66600.	2.5	35
49	Detection of respiratory syncytial virus defective genomes in nasal secretions is associated with distinct clinical outcomes. <i>Nature Microbiology</i> , 2021, 6, 672-681.	13.3	35
50	Evaluation of the Calu-3 cell line as a model of in vitro respiratory syncytial virus infection. <i>Journal of Virological Methods</i> , 2011, 174, 144-149.	2.1	33
51	The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein. <i>Virology</i> , 2021, 559, 1-9.	2.4	29
52	Using urine metabolomics to understand the pathogenesis of infant respiratory syncytial virus (RSV) infection and its role in childhood wheezing. <i>Metabolomics</i> , 2018, 14, 135.	3.0	28
53	The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection. <i>Vaccines</i> , 2017, 5, 16.	4.4	25
54	Exclusive breast-feeding, the early-life microbiome and immune response, and common childhood respiratory illnesses. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 612-621.	2.9	23

#	ARTICLE	IF	CITATIONS
55	Recombinant Protein-Based Assays for Detection of Antibodies to Severe Acute Respiratory Syndrome Coronavirus Spike and Nucleocapsid Proteins. <i>Vaccine Journal</i> , 2007, 14, 331-333.	3.1	22
56	A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response. <i>Viruses</i> , 2018, 10, 38.	3.3	22
57	Functional Features of the Respiratory Syncytial Virus G Protein. <i>Viruses</i> , 2021, 13, 1214.	3.3	21
58	Decrease in Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) Enhanced Disease with RSV G Glycoprotein Peptide Immunization in BALB/c Mice. <i>PLoS ONE</i> , 2013, 8, e83075.	2.5	17
59	Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0256482.	2.5	16
60	Effect of Infant RSV Infection on Memory T Cell Responses at Age 2-3 Years. <i>Frontiers in Immunology</i> , 2022, 13, 826666.	4.8	16
61	Development of a recombinant truncated nucleocapsid protein based immunoassay for detection of antibodies against human coronavirus OC43. <i>Journal of Virological Methods</i> , 2011, 177, 100-106.	2.1	15
62	Mutation of Respiratory Syncytial Virus G Protein's CX3C Motif Attenuates Infection in Cotton Rats and Primary Human Airway Epithelial Cells. <i>Vaccines</i> , 2019, 7, 69.	4.4	15
63	CX3CR1 Engagement by Respiratory Syncytial Virus Leads to Induction of Nucleolin and Dysregulation of Cilium-Related Genes. <i>Journal of Virology</i> , 2021, 95, .	3.4	14
64	Nasopharyngeal Haemophilus and local immune response during infant respiratory syncytial virus infection. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1097-1101.e6.	2.9	12
65	Metabolic Reprogramming of Nasal Airway Epithelial Cells Following Infant Respiratory Syncytial Virus Infection. <i>Viruses</i> , 2021, 13, 2055.	3.3	12
66	Upper respiratory tract bacterial-immune interactions during respiratory syncytial virus infection in infancy. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 966-976.	2.9	11
67	RSV Strains and Disease Severity. <i>Journal of Infectious Diseases</i> , 2019, 219, 514-516.	4.0	10
68	MUC5AC Levels Associated With Respiratory Syncytial Virus Disease Severity. <i>Clinical Infectious Diseases</i> , 2018, 67, 1441-1444.	5.8	9
69	A Respiratory Syncytial Virus Attachment Gene Variant Associated with More Severe Disease in Infants Decreases Fusion Protein Expression, Which May Facilitate Immune Evasion. <i>Journal of Virology</i> , 2020, 95, .	3.4	8
70	Protective role of Indoleamine 2,3 dioxygenase in Respiratory Syncytial Virus associated immune response in airway epithelial cells. <i>Virology</i> , 2017, 512, 144-150.	2.4	7
71	Two RSV Platforms for G, F, or G+F Proteins VLPs. <i>Viruses</i> , 2020, 12, 906.	3.3	7
72	In vitro model for the assessment of human immune responses to subunit RSV vaccines. <i>PLoS ONE</i> , 2020, 15, e0229660.	2.5	6

#	ARTICLE	IF	CITATIONS
73	Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay. <i>Journal of Immunological Methods</i> , 2021, 488, 112900.	1.4	6
74	Seasonal Timing of Infant Bronchiolitis, Apnea and Sudden Unexplained Infant Death. <i>PLoS ONE</i> , 2016, 11, e0158521.	2.5	5
75	Detection of RSV Antibodies in Human Plasma by Enzyme Immunoassays. <i>Methods in Molecular Biology</i> , 2016, 1442, 41-52.	0.9	3
76	Sex-specific association between prenatal life stress exposure and infant pro-inflammatory cytokine levels during acute respiratory infection. <i>Brain, Behavior, and Immunity</i> , 2019, 76, 275-279.	4.1	3
77	Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. <i>Microbiology Spectrum</i> , 2021, 9, e0045821.	3.0	3
78	Ability of device to collect bacteria from cough aerosols generated by adults with cystic fibrosis. <i>F1000Research</i> , 2016, 5, 1920.	1.6	3
79	Performance evaluation of antibody tests for detecting infant respiratory syncytial virus infection. <i>Journal of Medical Virology</i> , 2021, 93, 3439-3445.	5.0	3
80	The Challenge of Respiratory Syncytial Virus Human Challenge Studies. <i>New England Journal of Medicine</i> , 2022, 386, 696-697.	27.0	3
81	Functional antibody-dependent cell mediated cytotoxicity (ADCC) responses to vaccine and circulating influenza strains following vaccination. <i>Virology</i> , 2022, 569, 44-55.	2.4	2
82	1340. The Burden of Influenza and Rhinovirus Among Hospitalized Adults Post the COVID-19 Pandemic. <i>Open Forum Infectious Diseases</i> , 2021, 8, S757-S758.	0.9	1
83	Secretory Expression and Purification of Respiratory Syncytial Virus G and F Proteins in Human Cells. <i>Methods in Molecular Biology</i> , 2016, 1442, 53-62.	0.9	0
84	2314. Burden of Respiratory Syncytial Virus (RSV) Infection Among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF). <i>Open Forum Infectious Diseases</i> , 2019, 6, S793-S794.	0.9	0
85	1329. Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF). <i>Open Forum Infectious Diseases</i> , 2021, 8, S752-S753.	0.9	0
86	1334. Outcomes Among Influenza and SARS-CoV-2 Infection in Hospitalized Adults Age ≥ 50 Years and with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF). <i>Open Forum Infectious Diseases</i> , 2021, 8, S755-S755.	0.9	0